GlaxoSmithKline has acquired from Roche exclusive rights to the weight-loss medicine, orlistat, for over-the-counter (OTC) use in markets outside the US, excluding Japan.
GSK anticipates filing orlistat for OTC approval in Europe and certain key international markets by the end of 2007.
Earlier this month, GSK received FDA approval to market OTC orlistat in the USA under the brand name alli™, and expects to launch it during the summer.
No comments:
Post a Comment